The efficacy of deferoxamine to prevent hepatic fibrosis in children being treated with Anthracyclins
Phase 3
- Conditions
- Hepatic fibrosis.Hepatic fibrosis
- Registration Number
- IRCT2016080315666N4
- Lead Sponsor
- Vice chancellor of research, Shiaz Univeisity of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
signing informed consent; male or female aged between 2-18 years at screening; new pediatric cancer patients who are going to receive Anthracyclin drugs as part of their chemotherapy regimen. Exclusion criteria: patients below two years old; patients with previous history of treatment with any kind of chemotherapy or radiotherapy; diagnosis of primary or metastatatic hepatic tumors, chronic liver disease and liver cirrhosis.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver function test. Timepoint: before and after chemotherapy coarse. Method of measurement: hematology analysis.;Hyaluronic acid. Timepoint: before and after chemotherapy coarse. Method of measurement: FDM analysis kit.;Gamma-microglobulin. Timepoint: before and after chemotherapy coarse. Method of measurement: hematology analysis.;Liver fibrosis. Timepoint: before and after chemotherapy coarse. Method of measurement: liver fibroscan.;Liver dysfunction signs. Timepoint: before and after chemotherapy coarse. Method of measurement: Sonograghy.
- Secondary Outcome Measures
Name Time Method